» Articles » PMID: 29751586

Telomere Maintenance Mechanisms in Cancer

Overview
Journal Genes (Basel)
Publisher MDPI
Date 2018 May 13
PMID 29751586
Citations 68
Authors
Affiliations
Soon will be listed here.
Abstract

Tumour cells can adopt telomere maintenance mechanisms (TMMs) to avoid telomere shortening, an inevitable process due to successive cell divisions. In most tumour cells, telomere length (TL) is maintained by reactivation of telomerase, while a small part acquires immortality through the telomerase-independent alternative lengthening of telomeres (ALT) mechanism. In the last years, a great amount of data was generated, and different TMMs were reported and explained in detail, benefiting from genome-scale studies of major importance. In this review, we address seven different TMMs in tumour cells: mutations of the promoter (), amplification of the genes and , polymorphic variants of the gene and of its promoter, rearrangements of the gene, epigenetic changes, ALT, and non-defined TMM (NDTMM). We gathered information from over fifty thousand patients reported in 288 papers in the last years. This wide data collection enabled us to portray, by organ/system and histotypes, the prevalence of mutations, and amplifications, and ALT in human tumours. Based on this information, we discuss the putative future clinical impact of the aforementioned mechanisms on the malignant transformation process in different setups, and provide insights for screening, prognosis, and patient management stratification.

Citing Articles

Emergence and Cytogenetic Clonal Evolution of Chromosome 7 Abnormalities in Myeloid Malignancies: Investigating the Role of Telomere Dysfunction.

Baldazzi C, Bandini L, Robustelli V, Patuelli A, Venturi C, Grassi A Int J Mol Sci. 2025; 26(3).

PMID: 39940930 PMC: 11817968. DOI: 10.3390/ijms26031162.


Analysis of TERT mRNA Levels and Clinicopathological Features in Patients with Peritoneal Mesothelioma.

dAmati A, Serio G, Quaranta A, Vimercati L, De Giorgis M, Lorusso L Cancers (Basel). 2025; 17(2).

PMID: 39858033 PMC: 11764446. DOI: 10.3390/cancers17020252.


Case Report: Efficacy of anlotinib and sintilimab in treating lung adenocarcinoma with RET fusion and PD-L1 expression.

Bao H, Zhang J, Wang Y, Chen Z, Luo X, Li T Front Pharmacol. 2024; 15:1448291.

PMID: 39669196 PMC: 11635301. DOI: 10.3389/fphar.2024.1448291.


Improved Effectiveness of Combined Screening for Multiple Cancers: A Government-Organized Population-Based Study in China.

Lu Q, Liang D, Shi J, Wu S, Du X, He Y Cancer Med. 2024; 13(23):e70463.

PMID: 39606803 PMC: 11602753. DOI: 10.1002/cam4.70463.


TERTmonitor Efficacy and Performance in Detecting Mutations by Droplet Digital PCR.

Bessa-Goncalves M, Bras J, Jesus T, Prazeres H, Soares P, Vinagre J Genes (Basel). 2024; 15(11).

PMID: 39596624 PMC: 11594489. DOI: 10.3390/genes15111424.


References
1.
MacNeil D, Bensoussan H, Autexier C . Telomerase Regulation from Beginning to the End. Genes (Basel). 2016; 7(9). PMC: 5042394. DOI: 10.3390/genes7090064. View

2.
Liu X, Qu S, Liu R, Sheng C, Shi X, Zhu G . TERT promoter mutations and their association with BRAF V600E mutation and aggressive clinicopathological characteristics of thyroid cancer. J Clin Endocrinol Metab. 2014; 99(6):E1130-6. PMC: 4037723. DOI: 10.1210/jc.2013-4048. View

3.
Jin G, Xu L, Shu Y, Tian T, Liang J, Xu Y . Common genetic variants on 5p15.33 contribute to risk of lung adenocarcinoma in a Chinese population. Carcinogenesis. 2009; 30(6):987-90. DOI: 10.1093/carcin/bgp090. View

4.
Amorim J, Santos G, Vinagre J, Soares P . The Role of ATRX in the Alternative Lengthening of Telomeres (ALT) Phenotype. Genes (Basel). 2016; 7(9). PMC: 5042396. DOI: 10.3390/genes7090066. View

5.
Fan X, Wang Y, Kratz J, Brat D, Robitaille Y, Moghrabi A . hTERT gene amplification and increased mRNA expression in central nervous system embryonal tumors. Am J Pathol. 2003; 162(6):1763-9. PMC: 1868122. DOI: 10.1016/S0002-9440(10)64311-8. View